Minerva Neurosciences, Inc. (NERV)

NASDAQ: NERV · IEX Real-Time Price · USD
9.44
+0.34 (3.74%)
Sep 27, 2022 3:44 PM EDT - Market open
3.74%
Market Cap 50.41M
Revenue (ttm) n/a
Net Income (ttm) -48.99M
Shares Out 5.34M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE 11.21
Dividend n/a
Ex-Dividend Date Jun 21, 2022
Volume 290,108
Open 9.20
Previous Close 9.10
Day's Range 8.71 - 9.80
52-Week Range 2.51 - 16.08
Beta -0.22
Analysts Buy
Price Target 37.06 (+292.6%)
Earnings Date Nov 7, 2022

About NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import ... [Read more...]

Industry Biotechnology
IPO Date Jul 1, 2014
CEO Remy Luthringer
Employees 9
Stock Exchange NASDAQ
Ticker Symbol NERV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for NERV stock is "Buy." The 12-month stock price forecast is 37.06, which is an increase of 292.58% from the latest price.

Price Target
$37.06
(292.58% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NERV, FAZE: The Top 5 Short Squeeze Stocks This Week

Source: Shutterstock Short squeeze stocks are still worth keeping track of as traders look for potential gains this week! This has us turning to Fintel and its Short Squeeze Leaderboard for the latest s...

Other symbols: FAZEGETYMICSPETZ
1 day ago - InvestorPlace

NRBO, FAZE: The Top 5 Short Squeeze Stocks to Watch This Week

Source: Alextype/Shutterstock.com Traders continue to show interest in short squeeze stocks this week as they seek out likely targets to push higher. This has us checking out Fintel's Short Squeeze Lead...

Other symbols: FAZENRBOGLSISURG
1 week ago - InvestorPlace

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

BURLINGTON, Mass., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv...

2 weeks ago - GlobeNewsWire

Billionaire Steven Cohen Just Made a Big Bet on Minerva Neurosciences (NERV) Stock

Shares of Minerva Neurosciences (NASDAQ: NERV ) are soaring higher by over 70%  following a purchase by Steve Cohen's Point72 Asset Management and the company's submission of a new drug application (NDA...

1 month ago - InvestorPlace

Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up

Minerva's (NERV) stock surges after the company files an NDA-seeking FDA approval for its schizophrenia therapy.

1 month ago - Zacks Investment Research

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in ...

WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...

1 month ago - GlobeNewsWire

Here's Why Minerva Neurosciences (NERV) Could be Great Choice for a Bottom Fisher

Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement ...

1 month ago - Zacks Investment Research

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Third Quarter of 2022 Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Thir...

1 month ago - GlobeNewsWire

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022 Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter ...

4 months ago - GlobeNewsWire

Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Minerva Neurosciences Inc (NASDAQ: NERV) received the official meeting minutes from the Type C meeting with the FDA regarding the development of roluperidone for negative symptoms in schizophrenia. The ...

5 months ago - Benzinga

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a ...

Company to Host Webcast Wednesday, April 13, 2022 at 11am ET Company to Host Webcast Wednesday, April 13, 2022 at 11am ET

5 months ago - GlobeNewsWire

Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 40% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat centr...

6 months ago - GlobeNewsWire

Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Trial Results Confirm the Potential of Roluperidone To Treat Negative Symptoms and Improve Everyday Functioning in Patients with Schizophrenia Trial Results Confirm the Potential of Roluperidone To Trea...

6 months ago - GlobeNewsWire

Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Company to Host Conference Call Today at 8:30 a.m. ET

10 months ago - GlobeNewsWire

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as ...

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...

10 months ago - GlobeNewsWire

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

Management to Host Conference Call Management to Host Conference Call

10 months ago - GlobeNewsWire

Minerva Neurosciences Announces Promotion of Geoff Race to President

Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA

11 months ago - GlobeNewsWire

Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

Minerva Neurosciences Inc (NASDAQ: NERV) announced results from a bioequivalence study comparing roluperidone formulations used in Phase 2b and Phase 3 trials and the planned commercial formulation.  Re...

11 months ago - Benzinga

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commerci...

Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration

11 months ago - GlobeNewsWire

Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of -47.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...

1 year ago - GlobeNewsWire

Analysts Estimate Minerva Neurosciences (NERV) to Report a Decline in Earnings: What to Look Out for

Minerva Neurosciences (NERV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research